ConductScience.org, home

Paper384248

Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.

Hull R and 7 others. N Engl J Med, 1979. Cited by 594 papers, by iCite.

Cite this record

ConductScience Library. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. Papers, record 384248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/384248

Download JSON
Disease
venous thromboembolism33 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
PubMed
Journal
N Engl J Med
PubMed
Year
1979
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
594
iCite
Relative citation ratio, by iCite
24.3
iCite
Revised in PubMed
2022-03-11
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hull RR
2Delmore TT
3Genton EE
4Hirsh JJ
5Gent MM
6Sackett DD
7McLoughlin DD
8Armstrong PP

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HeparinMajor topic
ThrombophlebitisMajor topic
WarfarinMajor topic
Acute Disease
Clinical Trials as Topic
Female
Hemorrhage
Humans
Infusions, Parenteral
Injections, Subcutaneous
Male
Middle Aged
Prothrombin Time
Recurrence
Time Factors

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04981327The API-CALF Study: Apixaban to Treat Calf Vein ThrombosisResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by72

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 594 citations.

PMIDTitleJournalYearIn PapersSource
31858829Principal Component Analysis on Recurrent Venous Thromboembolism.Clin Appl Thromb Hemost2019https://conductscience.org/library/papers/31858829PubMed
30546748Dramatic response to low-dose rivaroxaban in an Asian patient with deep vein thrombosis and pulmonary embolism.J Cardiol Cases2013https://conductscience.org/library/papers/30546748PubMed
29791520Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension.Clinics (Sao Paulo)2018https://conductscience.org/library/papers/29791520PubMed
29399516Below-knee deep vein thrombosis (DVT): diagnostic and treatment patterns.Cardiovasc Diagn Ther2017https://conductscience.org/library/papers/29399516PubMed
29034033Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions.Ann Vasc Dis2017https://conductscience.org/library/papers/29034033PubMed
28737834Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.Cochrane Database Syst Rev2017https://conductscience.org/library/papers/28737834PubMed
27699156Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines.Vasc Specialist Int2016https://conductscience.org/library/papers/27699156PubMed
27167437New anticoagulants for the treatment of venous thromboembolism.J Bras Pneumol2016https://conductscience.org/library/papers/27167437PubMed
27122927Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.Acta Cardiol Sin2016https://conductscience.org/library/papers/27122927PubMed
25676529Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.Acad Emerg Med2015https://conductscience.org/library/papers/25676529PubMed
25506267Treatment options for venous thromboembolism: lessons learnt from clinical trials.Thromb J2014https://conductscience.org/library/papers/25506267PubMed
25398066Sex differences in patients receiving anticoagulant therapy for venous thromboembolism.Medicine (Baltimore)2014https://conductscience.org/library/papers/25398066PubMed
25300410New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.Drugs2014https://conductscience.org/library/papers/25300410PubMed
25092359Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.Cochrane Database Syst Rev2014https://conductscience.org/library/papers/25092359PubMed
23829521Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism.Thromb J2013https://conductscience.org/library/papers/23829521PubMed
23398560Sulfation patterns determine cellular internalization of heparin-like polysaccharides.Mol Pharm2013https://conductscience.org/library/papers/23398560PubMed
23344704Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach.Curr Treat Options Cardiovasc Med2013https://conductscience.org/library/papers/23344704PubMed
23049730Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.PLoS One2012https://conductscience.org/library/papers/23049730PubMed
22315268Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest2012https://conductscience.org/library/papers/22315268PubMed
21765670Medical management of venous thromboembolic disease.Ochsner J2000https://conductscience.org/library/papers/21765670PubMed

See all 72 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
APIXABANCHEMBL231779Results1https://conductscience.org/library/drugs/CHEMBL231779

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/384248

GET https://conductscience.org/api/papers/v1/384248/cited_by?page=2